Rigel Pharmaceuticals Stock News

Neurocrine (NBIX) delivered earnings and revenue surprises of -113.11% and 1.22%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Rigel PharmaceuticalsA Biopharma With A Free Shot On Goal In COVID-19, With A Pipeline As A Safety Net

In this article we are going to use hedge fund sentiment as a tool and determine whether Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is a good investment right now.

Shares of Rigel Pharmaceuticals are down today as the company announced that its Q4 2021 net product sales would be down slightly from where it was in the year-ago period.

SOUTH SAN FRANCISCO, Calif., Jan. 10, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is sched

SOUTH SAN FRANCISCO, Calif., Jan. 10, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today provided a business update including preliminary 2021 full-year total revenue, the status of the Phase 3 study in COVID-19, and upcoming catalysts in

SOUTH SAN FRANCISCO, Calif. , Jan. 7, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL ) today reported the grant of stock options to purchase an aggregate of 610,000 shares of common stock to 14 newly hired employees. These awards were approved by the Compensation Committee of Rigel''s Board of Directors and granted pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, as amended, with a grant date of January 6, 2022 , as an inducement material to the new employees entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4). The stock options have an exercise price of $2.62 per share, the price at the close of trading of Rigel''s common stock on January 6, 2022 . The stock options awards vest over a four-year period, with one-fourth of the shares subject to such awards vesting on the first anniversary of the award''s vesting commencement date, and the remaining shares vesting in equal monthly installments thereafter. Full story available on Benzinga.

Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) has a beta value of 1.43 and has seen 1.52 million shares traded in the last trading session. The company, currently valued at $434.96M, closed the last trade at $2.71 per share which meant it gained $0.04 on the day or 1.50% during that session. The RIGL stock price is -102.95% Why Acquire Shares Of Rigel Pharmaceuticals Inc. (RIGL)? Read More »

TOKYO (dpa-AFX) - Rigel Pharmaceuticals, Inc. (RIGL) announced Tuesday that its collaboration partner, Kissei Pharmaceutical Co., Ltd., has released positive topline results from its Phase 3 clini

Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) shares, rose in value on Friday, 12/17/21, with the stock price up by 6.56% to the previous days close as strong demand from buyers drove the stock to $2.60. Actively observing the price movement in the last trading, the stock closed the session at $2.44, falling within a range of $2.425 Rigel Pharmaceuticals Inc. (NASDAQ: RIGL): Overvalued In Comparison To Others? Read More »

Analysts forecast that Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) will post sales of $23.12 million for the current quarter, Zacks reports. Three analysts have provided estimates for Rigel Pharmaceuticals earnings, with the lowest sales estimate coming in at $22.93 million and the highest estimate coming in at $23.48 million. Rigel Pharmaceuticals reported sales of $18.45 million during []

Rigel Pharmaceuticals (NASDAQ:RIGL) was downgraded by research analysts at TheStreet from a c- rating to a d+ rating in a research report issued to clients and investors on Wednesday, TheStreetRatingsTable reports. RIGL has been the topic of several other reports. BMO Capital Markets restated a buy rating and set a $8.00 price target on shares []

Wall Street brokerages expect Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) to report ($0.12) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Rigel Pharmaceuticals earnings. The lowest EPS estimate is ($0.13) and the highest is ($0.10). Rigel Pharmaceuticals posted earnings of ($0.11) per share in the same []

Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) traded at $2.67 at close of the session on Tuesday, 11/30/21, made a downward move of -1.11% on its previous days price. Looking at the stock we see that its previous close was $2.70 and the beta (5Y monthly) reads 1.55 with the days price range being $2.59 $2.74. In Rigel Pharmaceuticals Inc.s Stock Price Relatively Down Recently, But Trouble Is Still Brewing Read More »